Aerovance (Berkeley, CA) a biopharmaceutical company focused on the development asthma, cystic fibrosis and chronic obstructive pulmonary disease has closed a $60M Series C. Participants in the round included Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & CO.

